The problem is that at about age 30, adults already begin losing muscle at about 3-5%  every 10 years, according to the ...

GLP-1 drugs like (Ozempic and Wegovy) have finally started to make weight loss a sustainable reality for many people with ...

Structure Therapeutics has touted the 16% weight loss—about 39 pounds—seen by aleniglipron as the best results yet for an oral GLP-1 drug, as the obesity biotech readies the candidate for phase 3. The ...

Wegovy is a Food and Drug Administration-approved weight loss medication for people with obesity or those who are overweight with weight-related health conditions. In recent years, interest in ...

Analysts remain intrigued by aleniglipron’s potential in the oral GLP-1RA market, though they note it is too early to compare the drug’s efficacy to Eli Lilly’s orforglipron.

Some patients taking popular GLP-1 weight loss drugs may be able to keep the weight off while taking injections less often, ...

CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist. Topline data were ...

Structure Therapeutics’ oral obesity drug aleniglipron delivered up to 16.3 per cent weight loss when compared with a placebo ...

With India’s semaglutide patent expiring on 20 March, about 50 branded generics are expected to enter the market.